Johnson & Johnson is entering the final stage of its clinical trial to determine if its experimental single-dose COVID-19 vaccine can protect against the virus. Johnson & Johnson entered Phase III of clinical trials for its experimental coronavirus vaccine on Wednesday. J&J's vaccine combines genetic material from the new virus with the genes of the adenovirus - which causes the common cold - to induce an immune response. Unlike those of other drugmakers, J&J's vaccine does not need to be frozen and may require only one dose instead of two. Health and Human Services Secretary Alex Azar said the COVID-19 vaccine campaign will build on longstanding cooperation between the federal government and the states on immunizations.

Source: Daily Mail September 23, 2020 14:29 UTC